US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 
• By Derrick Gingery

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.

FDA scientists and reviewers continue to write guidances, but the ability to publish them has been curtailed. (Shutterstock)

More from Generics

More from Biosimilars & Generics